Business profile & competitive position
The Cooper Companies, Inc. operates inside the Healthcare sector, specifically the Medical – Instruments & Supplies industry. It runs two global medical-device segments. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses and specialty eyecare products, including silicone hydrogel lenses, orthokeratology and scleral lenses, plus myopia-management products led by the MiSight 1 day lens. CooperSurgical supplies more than 600 products and services focused on fertility and women’s health, including gynecology and obstetrics devices, contraception products, labor-and-delivery tools, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services. The company says its products reach more than 130 countries and positively affect over 50 million lives per year.
The financial profile gives a mixed read on competitive strength. A 13.5% net margin shows Cooper can price its contact-lens and fertility products above its manufacturing and distribution costs. However, a 6.9% return on equity is modest for an established medical-device name; it implies that the asset base—driven by manufacturing capacity, global distribution, acquisitions and R&D spending—absorbs a meaningful share of profits before reaching shareholders. With approximately 500 R&D employees split across both segments, the company is clearly reinvesting to defend shelf space and clinical credibility, but the ROE figure suggests the economic moat is solid rather than exceptionally wide.
Financial posture
At the time of this snapshot, Cooper Companies carries an $11.9 billion market capitalization and trades at a P/E multiple of 21.3. The stock price is $62.36, sitting above its 50-day exponential moving average of $60.94, with an RSI of 58.1—neither oversold nor overbought on a short-term basis. A beta of 0.82 indicates the stock has moved somewhat less than the broad market, which is typical for a healthcare staples-like device company.
Profitability metrics frame the valuation. The 13.5% net margin confirms operations are profitable, while the 6.9% ROE is the figure that should catch a fundamental analyst’s eye. For a business trading at 21.3x earnings, that ROE is low enough that a buyer is effectively paying for future margin expansion, successful new product launches, or accretive M&A rather than for current returns on book equity. Debt is not the central theme in the data provided, but the combination of a moderate P/E, respectable margin and lowish ROE points to a reliably cash-generative company that is still carrying a capital-intensive balance sheet.
Strategic priorities & outlook
The company’s most recent SEC 10-K filing outlines four operational priorities. First, CooperVision is pushing for greater worldwide market penetration of recently introduced lenses and expanding its presence in both existing and emerging markets. Second, it is increasing investment in distribution and packaging capabilities to support growth and service quality. Third, CooperVision is spending to develop the myopia-management market by educating eye-care practitioners, patients and families, which ties directly to the MiSight 1 day approval profile. Fourth, CooperSurgical expects to keep investing in its business, including through strategic transactions, to broaden its integrated-solutions model across fertility and women’s health.
Two product-level facts stand out: MiSight 1 day is the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children; and CooperSurgical’s catalog exceeds 600 products and services. The strategy is therefore not a single-product bet. It is a dual-platform push: grow share in the core contact-lens market while building specialized clinical ecosystems around myopia management and fertility services.
Macro & geopolitical exposure
Because Cooper Companies sits in Medical – Instruments & Supplies, its exposures are those of a global, regulated medical-device business rather than a commodity or consumer-discretionary company. Key macro factors include:
- Regulatory and approval risk: Contact lenses and fertility devices require clearances from bodies such as the FDA, China’s NMPA and Japan’s MHLW. Approval timing, labeling and post-market surveillance can shape revenue trajectories.
- Reimbursement and payor dynamics: portions of CooperSurgical’s fertility and women’s-health portfolio are sensitive to insurance coverage, government reimbursement policies and broader healthcare spending.
- Currency and international sales: with products sold in more than 130 countries, reported revenue is exposed to dollar strength or weakness against the euro, yen, renminbi and emerging-market currencies.
- Supply chain and trade policy: contact lenses rely on specialized polymers, packaging and manufacturing equipment; tariffs or freight disruptions can affect input costs and margins.
- Demographics and public health trends: demand is tied to myopia prevalence, aging populations, birth-rate trends and fertility-treatment utilization.
These forces are industry-level tailwinds and headwinds, not company-specific guarantees. They do, however, explain why a medical-device stock can look steady on a beta basis while still experiencing headline volatility from regulation, litigation or reimbursement news.
Recent developments
The most visible recent headlines involve securities litigation rather than product launches. On November 8, 2026, newsfilecorp.com reported that Rosen Law Firm, described as “regarded investor counsel,” was encouraging Cooper Companies investors to inquire about a securities class-action investigation. Similar announcements appeared on November 6 and November 5 from Rosen Law Firm via globenewswire.com and prnewswire.com respectively. On November 5, 2026, CooperCompanies separately announced that its fourth-quarter and full-year 2026 results will be released on December 3, 2026—after market close.
The litigation headlines create headline risk and can pressure sentiment even when the core business reports in-line or better-than-expected earnings. The company has not provided details on the allegations in the data available, so the materiality is uncertain, but the clustering of announcements around the earnings-release date means traders should treat the December 3 report as both a fundamental event and a potential catalyst for any legal overhang.
Earnings behavior & post-earnings drift
Cooper Companies’ recent earnings record is statistically strong on the headline beat metric but much more complicated on price reaction. Over the last eight reported quarters, the company beat the consensus estimate in all eight periods, a 100% beat rate, with an average positive surprise of 4.2%. Yet the average five-trading-day move after those reports was -2.34%, classified as a downward post-earnings drift. That is the key disconnect: beats do not automatically translate into sustained upward moves.
The most recent four quarters illustrate the pattern clearly:
- September 9, 2026: actual EPS of $1.15 versus the $1.12 estimate, a 2.7% positive surprise. The stock fell 14.67% the next session and 13.97% over the following five days.
- June 4, 2026: actual EPS of $1.21 versus the $1.10 estimate, a 10.0% positive surprise. The stock rose 8.58% the next day and finished the next five days up 8.85%.
- March 5, 2026: actual EPS of $1.10 versus the $1.03 estimate, a 6.8% positive surprise. The stock dropped 4.55% the next day and 10.82% over the next five days.
- December 4, 2025: actual EPS of $1.15 versus the $1.11 estimate, a 3.6% positive surprise. The stock gained 5.67% the next day and 6.59% over the following five days.
So the beat itself is not the whole story; guidance, margin commentary, segment mix, currency impacts and broader sentiment appear to drive the after-hours and post-earns drift more than the headline EPS number. The average five-day drift remains negative despite the 100% beat rate, which should caution anyone assuming that a beat on the upcoming report guarantees a pop. The next scheduled release is December 3, 2026 after the close, with a current consensus EPS estimate of $1.07.
Frequently Asked Questions
What are the two main businesses of The Cooper Companies?
CooperVision develops and sells contact lenses and specialty eyecare products, including the myopia-management MiSight 1 day lens. CooperSurgical provides fertility and women’s health devices and services, with more than 600 products and services in its portfolio.
Why has Cooper Companies’ stock sometimes fallen after earnings beats?
Over the last eight quarters the company beat EPS estimates 100% of the time with an average surprise of 4.2%, yet the average five-day post-earnings drift was -2.34%. Forward guidance, segment margins, currency impacts and broader sentiment can outweigh the headline beat, as seen when the September 9, 2026 beat was followed by a 13.97% five-day decline.
When does Cooper Companies report next, and what is the consensus?
The company is scheduled to report fourth-quarter and full-year 2026 results on December 3, 2026 after the market closes. The current consensus EPS estimate is $1.07.
For a deeper dive into how institutional analysts weigh the litigation overhang, the fertility-demand outlook and CooperVision’s myopia-management trajectory, review the full institutional verdict on this ticker.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-09-09 | $1.15 | $1.12 | +2.7% | -14.67% | -13.97% |
| 2026-06-04 | $1.21 | $1.1 | +10% | +8.58% | +8.85% |
| 2026-03-05 | $1.1 | $1.03 | +6.8% | -4.55% | -10.82% |
| 2025-12-04 | $1.15 | $1.11 | +3.6% | +5.67% | +6.59% |
| 2025-08-27 | $1.1 | $1.07 | +2.8% | - | - |
| 2025-05-29 | $0.96 | $0.928 | +3.4% | - | - |
Previous COO editions
Get the institutional verdict on COO
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the COO verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.